Marinus Pharmaceuticals (NASDAQ: MRNS) was one of the top gainers in Wednesday’s trading session, and closed the day with gains of 37.98%. This followed the company’s clinical and regulatory updates for its orphan seizure programs in tuber sclerosis complex (TSC), PCDH-19